ArticleInflammatory bowel diseases2024
Obesity, Sarcopenia and Myosteatosis: Impact on Clinical Outcomes in the Operative Management of Crohn's Disease.
Article in Inflammatory bowel diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Risk Factors and Predictive Biomarkers for Postoperative Complications in Crohn's Disease Surgery: Systematic Review.International journal of molecular sciences · 2026Pooled it
- Evaluating the role of sarcopenia in adverse clinical outcomes for Crohn's disease patients: a systematic review and meta-analysis.International journal of colorectal disease · 2025Pooled it
- Assessing causality between inflammatory bowel diseases with frailty index and sarcopenia: a bidirectional Mendelian randomization study.European journal of medical research · 2024Pooled it
- Myosteatosis is associated with adverse in-hospital outcomes and CONUT score in hospitalized internal medicine patients.Acta diabetologica · 2026Article
- Sarcopenia in Inflammatory Bowel Disease: Prevalence, Mechanisms, Detection, Adverse Clinical Impact and Targetable Care Gaps-A Narrative Review Supported by a Structured Literature Search.Life (Basel, Switzerland) · 2026Review
- Preoperative myopenia is associated with postoperative complications and endoscopic recurrence after ileocolic resection in Crohn's disease.Therapeutic advances in gastroenterology · 2026Article
- The Impact of Sarcopenia on Clinical Outcomes in Pediatric Crohn's Disease.Inflammatory bowel diseases · 2026Article
- Cancer-Associated Cachexia in the Era of Obesity.International journal of molecular sciences · 2025Review
- Artificial Intelligence-Derived Intramuscular Adipose Tissue Assessment Predicts Perineal Wound Complications Following Abdominoperineal Resection.World journal of surgery · 2025Article
- Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review.World journal of gastroenterology · 2025Review
- Dynamic CT-based body composition analysis predicts surgical risk in Crohn's disease with small bowel stenosis: a retrospective cohort study.Frontiers in medicine · 2025Article
- Article
- Review
- Assessment of body composition-related imaging parameters indicative of sarcopenia in Chinese patients with Crohn's disease: correlation with disease severity and biologic efficacy.American journal of translational research · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity, sarcopenia, and myosteatosis in inflammatory bowel disease may confer negative outcomes, but their prevalence and impact among patients with Crohn's disease (CD) have not been systematically studied. The aim of this study was to assess nutritional status and body composition among patients undergoing resectional surgery for CD and determine impact on operative outcomes.
methodsConsecutive patients with CD undergoing resection from 2000 to 2018 were studied. Total, subcutaneous, and visceral fat areas and lean tissue area (LTA) and intramuscular adipose tissue (IMAT) were determined preoperatively by computed tomography at L3 using SliceOmatic (Tomovision, Canada). Univariable and multivariable linear, logistic, and Cox proportional hazards regression were performed.
resultsOne hundred twenty-four consecutive patients were studied (ileocolonic disease 53%, n = 62, biologic therapy 34.4% n = 43). Mean fat mass was 22.7 kg, with visceral obesity evident in 23.9% (n = 27). Increased fat stores were associated with reduced risk of emergency presentation but increased corticosteroid use (β 9.09, standard error 3.49; P = .011). Mean LBM was 9.9 kg. Sarcopenia and myosteatosis were associated with impaired baseline nutritional markers. Myosteatosis markers IMAT (P = .002) and muscle attenuation (P = .0003) were associated with increased grade of complication. On multivariable analysis, IMAT was independently associated with increased postoperative morbidity (odds ratio [OR], 1.08; 95% confidence interval (CI), 1.01-1.16; P = .037) and comprehensive complications index (P = .029). Measures of adiposity were not associated with overall morbidity; however, increased visceral fat area independently predicted venous thromboembolism (OR, 1.02; 95% CI, 1.00-1.05; P = .028), and TFA was associated with increased wound infection (OR, 1.00; 95% CI, 1.00-1.01; P = .042) on multivariable analysis.
conclusionMyosteatosis is associated with nutritional impairment and predicts increased overall postoperative morbidity following resection for CD. Despite its association with specific increased postoperative risks, increased adiposity does not increase overall morbidity, reflecting preservation of nutritional status and relatively more quiescent disease phenotype. Impaired muscle mass and function represent an appealing target for patient optimization to improve outcomes in the surgical management of CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.